Abstract
Exendin-4 is a potent insulinotropic agent in diabetes patients; however, its therapeutic utility is limited due to the frequent injections required. In this study, an orally available exendin-4 formulation, using a pH-responsive NP, was developed. Following oral administration of 123I-labeled- exendin-4 loaded NPs in rats, the biodistribution of the administered drug was investigated using a dual isotope dynamic SPECT/CT scanner. The results showed that the radioactivity of 123I-exendin-4 propagated from the esophagus, stomach, and small intestine and then was absorbed into the systemic circulation; with time progressing, 123I-exendin-4 was metabolized and excreted into the urinary bladder.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 IFMBE
About this paper
Cite this paper
Nguyen, HN., Bui, TA., Nguyen, HG. (2013). Novel Nanoparticles for Oral Exendin-4 Delivery. In: Toi, V., Toan, N., Dang Khoa, T., Lien Phuong, T. (eds) 4th International Conference on Biomedical Engineering in Vietnam. IFMBE Proceedings, vol 49. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-32183-2_18
Download citation
DOI: https://doi.org/10.1007/978-3-642-32183-2_18
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-32182-5
Online ISBN: 978-3-642-32183-2
eBook Packages: EngineeringEngineering (R0)